Singh, Bhuchitra
Sims, Holly
Trueheart, Irene
Simpson, Khara
Wang, Karen C.
Patzkowsky, Kristin
Wegman, Thomas
Soma, Jean-Marie
Dixon, Rosina
Jayes, Friederike
Voegltine, Kristin
Yenokyan, Gayane
Su, Szu-Chi
Leppert, Phyllis
Segars, James H. http://orcid.org/0000-0001-5969-376X
Funding for this research was provided by:
Howard and Georgeanna Jones Foundation for Reproductive Medicine (NA)
Advance Biofractures Corp (NA-clinical research)
Article History
Received: 26 December 2020
Accepted: 2 April 2021
First Online: 29 April 2021
Declarations
:
: The study protocol and all procedures were approved by the Johns Hopkins School of Medicine IRB (IRB00091412).
: Dr. Rosina Dixon and Jean-Marie Soma are employed by BioSpecifics Technologies Corporation. The late Dr. Thomas Wegman was President of BioSpecifics Technologies Corporation. The study was funded by Advance Biofactures Corporation, Lynbrook, NY, a subsidiary of Biospecifics Technologies Corporation. Biospecifics staff participated in study design, secured the IND, and monitored study progress in keeping with industry standards, and manuscript preparation, but did not participate in subject recruitment, data collection, data analysis, and preparation of figures and tables or influence the presentation or interpretation of results, in keeping with the principles of the Messenden Code of Ethics and Accountability. J.H.S. is active on the following boards: The American Board of Obstetrics and Gynecology, the Society for Reproductive Investigation and the American Gynecological and Obstetrical Society. Dr. Segars has received sponsored research funding for clinical trials involving from Biospecifics, Bayer, and Abbvie and served as a consultant for Myovant. The other author(s) report(s) no conflicts of interest.